Riskpilot← Back to searchSign inGet full accessAB Extempore
ABActiveOrg 5591992952Hunnamålavägen 10Business and other management consultancy activities · NACE 7020Est. 20190 employees
Revenue 2024
SEK 200K
-93% vs 2023
EBITDA margin
86.2%
+110% vs 2023
Equity ratio
90.9%
Financial strength
Net profit 2024
SEK 178K
+110% vs 2023
| Revenue | SEK 200K | -93% |
| EBITDA | SEK 172K | +110% |
| Net profit | SEK 178K | +110% |
| Total assets | SEK 327K | -44% |
| Equity | SEK 297K | -43% |
| Employees | 0 | — |
Legal name
AB Extempore
Org number
5591992952
Legal form
Aktiebolag
NACE code
7020 · Business and other management consultancy activities
Founded
19 mars 2019
Share capital
SEK 100 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget skall bedriva verksamhet konsultverksamhet inom företagsledning.
Address
Hunnamålavägen 10
Email
david.jern@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 1 175 | 4 585 | 2 794 | 200 |
| Staff expenses | — | — | −887 | −611 | −0 |
| EBITDA | −2 | 486 | −657 | −1 698 | 172 |
| Depreciation & amort. | −0 | −14 | −170 | −170 | — |
| EBIT | −2 | 472 | −826 | −1 868 | 172 |
| Net financials | — | −17 | −22 | −3 | 6 |
| Profit before tax | −2 | 455 | — | — | 178 |
| Tax | −0 | −62 | −33 | 33 | — |
| Net profit | −2 | 393 | −880 | −1 838 | 178 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 1 640 | 3 537 | 2 794 | 580 | 327 |
| Equity | 1 244 | 1 738 | 1 857 | 519 | 297 |
| Long-term debt | 0 | 480 | 0 | — | — |
| Short-term debt | 395 | 1 320 | 936 | 61 | 30 |
| Total debt | 395 | 1 800 | 936 | 61 | 30 |
EBITDA margin
86.2%
This company
15.8%
Market median
+446% vs market
20202024
Equity ratio
90.9%
This company
38.2%
Market median
+138% vs market
20202024
Return on equity
59.8%
This company
18.4%
Market median
+225% vs market
20202024
Net profit margin
89.0%
This company
8.1%
Market median
+999% vs market
20202024
Asset turnover
0.61×
This company
1.12×
Market median
-46% vs market
20202024
Debt / equity
0.10×
This company
0.62×
Market median
+84% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2024 | |
| Board of Directors | 2020 | |
| Former (3) | ||
| Board of Directors | 2020 – 2020 | |
| Deputy Board Member | 2021 – 2024 | |
| Deputy Board Member | 2021 – 2021 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Bioswed Scientific AB
AB Extempore Board members of AB Extempore also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Carl Magnus Froste | Board of Directors | 0 companies |
| Gordon Patrik Talamo | Deputy Board Member | 0 companies |
| Karl Martin Östmark | Deputy Board Member | 0 companies |
| Annie Elisabeth Jern | Deputy Board Member | 0 companies |
| David Bengt Olof Jern | Board of Directors | 0 companies |